Clinical Trial Update: Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

A completed Phase 2 trial examined dose-dense biweekly docetaxel plus 5-fluorouracil as first-line treatment for advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Taxotere (docetaxel)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED